Cargando…
Diagnosis, quality of life, and treatment of patients with Hunter syndrome in the French healthcare system: a retrospective observational study
BACKGROUND: Mucopolysaccharidosis II (MPS II) is associated with a broad spectrum of chronic and progressive, life-limiting symptoms. Idursulfase is approved for MPS II enzyme replacement therapy (ERT) in over 50 countries. This retrospective study evaluated the MPS II burden, organization of clinic...
Autores principales: | Guffon, Nathalie, Heron, Bénédicte, Chabrol, Brigitte, Feillet, François, Montauban, Vincent, Valayannopoulos, Vassili |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407793/ https://www.ncbi.nlm.nih.gov/pubmed/25887606 http://dx.doi.org/10.1186/s13023-015-0259-0 |
Ejemplares similares
-
Miglustat therapy in the French cohort of paediatric patients with Niemann-Pick disease type C
por: Héron, Bénédicte, et al.
Publicado: (2012) -
Efficacy and safety of i.v. sodium benzoate in urea cycle disorders: a multicentre retrospective study
por: Husson, Marie-Caroline, et al.
Publicado: (2016) -
Orthopedic manifestations in patients with mucopolysaccharidosis type II (Hunter syndrome) enrolled in the Hunter Outcome Survey
por: Link, Bianca, et al.
Publicado: (2010) -
Effects of miglustat therapy on neurological disorder and survival in early-infantile Niemann-Pick disease type C: a national French retrospective study
por: Freihuber, Cécile, et al.
Publicado: (2023) -
Screening for primary creatine deficiencies in French patients with unexplained neurological symptoms
por: Cheillan, David, et al.
Publicado: (2012)